ssk
●    

2006-10-12 14:38
(7185 d 01:20 ago)

Posting: # 314
Views: 12,353
 

 Body Mass Index [Design Issues]

Dear all,
How does BMI of a subject affect a BA/BE study.What is the usual range of BMI to be taken for a study.
Thanking you,
ssk.
Jaime_R
★★  

Barcelona,
2006-10-12 21:04
(7184 d 18:54 ago)

@ ssk
Posting: # 316
Views: 10,567
 

 BMI

Hi ssk!

❝ How does BMI of a subject affect a BA/BE study.


In a cross-over design single dose study you will see hardly any influence at all (subjects act as their own control, differences mean out).
If you are performing a parallel design, the BMI probably should be narrower in oder to keep groups as homogenous as possible and minimize variability.

If you are planning a multiple dose study for a highly lipophilic drug (which rapidly distributes in body fat with a very slow elimination) based on single dose data you should be cautious, because the slow elimination will be more pronounced in subjects with a high BMI.

❝ What is the usual range of BMI to be taken for a study.


For healthy subjects in BE 18-29 kg/m² is quite common, but more restrictive ones like 18-27 kg/m² or even 20-25 kg/m² (making recruitment cumbersome - with only doubtful justification) are in practice.

For a discussion see this thread at David Bourne's PharmPK list.

Regards, Jaime
ghouse1111
●    

2006-12-17 09:20
(7119 d 05:38 ago)

(edited on 2006-12-18 11:59)
@ ssk
Posting: # 403
Views: 10,076
 

 BMI

Dear ssk,

the ideal BMI range to include a volunteer in study is 19-26kg/m2. If a person falls below or above the normal value it shows affect on drug distribution which indirectly shows affect on B.A.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2006-12-18 13:08
(7118 d 01:50 ago)

@ ghouse1111
Posting: # 405
Views: 10,365
 

 BMI

Dear ghouse1111!

the ideal BMI range to include a volunteer in study is 19-26kg/m2.


Is it? Who says?

If a person falls below or above the normal value it shows affect on drug distribution which indirectly shows affect on B.A.


I just made a quick survey of my most recent 110 studies - the ones I had in my online database - I was just too lazy to head for my backups. ;-)

I would support Jaime's point of view. 102 studies (93%) were performed in subjects with a BMI of 18–29 kg/m². I never got any problems in approval…

Just think about:
  • Differences in distribution (between subjects) simply mean out in a cross-over design.
  • At least for the FDA subjects should represent the population intended for treatment.
Since you made a strong statement (bold letters in you post…) do you have any reference or data supporting your statement?


Whenever a theory appears to you as the only possible one,
take this as a sign that you have neither understood the theory
nor the problem which it was intended to solve.
Karl R. Popper

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
ghouse1111
●    

2006-12-18 06:21
(7118 d 08:37 ago)

(edited on 2006-12-18 12:02)
@ Helmut
Posting: # 407
Views: 10,060
 

 BMI

Dear all,

I’ve told B.M.I should be between 19-26, because we’re following same value in our set up, upto date we have not encountered any problem with this range, that too our studies are carried out to market our drugs in US market.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2006-12-18 13:32
(7118 d 01:26 ago)

@ ghouse1111
Posting: # 410
Views: 10,342
 

 narrow BMI justified for BE?

Dear ghouse1111!

In my previous post I asked you for a justification of your statement.
'Following a set up' (or even worse, but often seen: 'because we have an SOP for it') is no science, but blind bureaucracy.

Now what have we got:
  • I have a number of studies with BMI of 18–29 kg/m²,
  • you have a number of studies (how many?) with BMI 19–26 kg/m²,
all of them showing no problems in approval. Fine.

I would strongly suggest to read the reference already given in Jaime's post.
BMI (or body weight, body surface,…) simply don't show up in the comparison of formulations for BE (… bridging studies are another issue).
Also see this retrospective analysis.

In the light of recent developments (matching characteristics of the population intended for treatment) I would advocate an even wider BMI-range than the one I used for many years! :smoke:

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
123 visitors (0 registered, 123 guests [including 26 identified bots]).
Forum time: 15:59 CEST (Europe/Vienna)

I have never in my life learned anything
from any man who agreed with me.    Dudley Field Malone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5